Supporting life science companies from proof-of-concept to commercialisation
Brandon Capital is Australasia's leading life science venture capital firm. Our strong global presence is supported by team members in the US and UK as well as key partners such as Callaghan Innovation. From early-stage seed investment through to expansion capital, Brandon Capital provides capital and shares expertise with life science companies from proof-of-concept through to commercialisation.
Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading Australian and New Zealand medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology which improve health and save lives.
Brandon Capital is Australasia's leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK.
Through collaboration, investment and knowledge sharing, we transform promising medical research into medical therapies that improve patients' lives globally.
We have supported over 50 start-up companies to-date, the majority of which were founded by us in collaboration with the inventors and their research institutions. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation.
Our team are professionals with technical, business and operational experience. We partner with entrepreneurs and have a proven track record of establishing successful, long-term relationships with our management teams. We know what it takes to maximise the chance of success for a life science company and this expertise is directed toward supporting our portfolio companies to a successful outcome.
With an unwavering focus on life sciences, we’re at the forefront of contributing to the growth of an exciting high-value, sustainable industry which delivers strong investment returns, creates jobs, and improves patient outcomes in New Zealand, Australia and globally.